Literature DB >> 27246369

Late Mortality and Causes of Death among Long-Term Survivors after Allogeneic Stem Cell Transplantation.

Yoshiko Atsuta1, Akihiro Hirakawa2, Hideki Nakasone3, Saiko Kurosawa4, Kumi Oshima5, Rika Sakai6, Kazuteru Ohashi7, Satoshi Takahashi8, Takehiko Mori9, Yukiyasu Ozawa10, Takahiro Fukuda4, Heiwa Kanamori11, Yasuo Morishima12, Koji Kato13, Hiromasa Yabe14, Hisashi Sakamaki7, Shuichi Taniguchi15, Takuya Yamashita4.   

Abstract

We sought to assess the late mortality risks and causes of death among long-term survivors of allogeneic hematopoietic stem cell transplantation (HCT). The cases of 11,047 relapse-free survivors of a first HCT at least 2 years after HCT were analyzed. Standardized mortality ratios (SMR) were calculated and specific causes of death were compared with those of the Japanese population. Among relapse-free survivors at 2 years, overall survival percentages at 10 and 15 years were 87% and 83%, respectively. The overall risk of mortality was significantly higher compared with that of the general population. The risk of mortality was significantly higher from infection (SMR = 57.0), new hematologic malignancies (SMR = 2.2), other new malignancies (SMR = 3.0), respiratory causes (SMR = 109.3), gastrointestinal causes (SMR = 3.8), liver dysfunction (SMR = 6.1), genitourinary dysfunction (SMR = 17.6), and external or accidental causes (SMR = 2.3). The overall annual mortality rate showed a steep decrease from 2 to 5 years after HCT; however, the decrease rate slowed after 10 years but was still higher than that of the general population at 20 years after HCT. SMRs in the earlier period of 2 to 4 years after HCT and 5 years or longer after HCT were 16.1 and 7.4, respectively. Long-term survivors after allogeneic HCT are at higher risk of mortality from various causes other than the underlying disease that led to HCT. Screening and preventive measures should be given a central role in reducing the morbidity and mortality of HCT recipients on long-term follow-up.
Copyright © 2016 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Causes of death; Late effects; Late mortality

Mesh:

Year:  2016        PMID: 27246369     DOI: 10.1016/j.bbmt.2016.05.019

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  16 in total

1.  Secondary esophageal squamous cell carcinoma after hematopoietic stem cell transplantation.

Authors:  Kosuke Nomura; Toshiro Iizuka; Daisuke Kaji; Yuki Asano-Mori; Yorinari Ochiai; Yugo Suzuki; Junnosuke Hayasaka; Satoshi Yamashita; Akira Matsui; Daisuke Kikuchi; Shuichi Taniguchi; Yutaka Takazawa; Shu Hoteya
Journal:  J Cancer Res Clin Oncol       Date:  2021-01-02       Impact factor: 4.553

2.  Long-term outcome and chimerism in patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation: a retrospective nationwide survey.

Authors:  Akihiro Iguchi; Yuko Cho; Hiromasa Yabe; Shunichi Kato; Koji Kato; Junichi Hara; Katsuyoshi Koh; Junko Takita; Takashi Ishihara; Masami Inoue; Kohsuke Imai; Hideki Nakayama; Yoshiko Hashii; Akira Morimoto; Yoshiko Atsuta; Tomohiro Morio
Journal:  Int J Hematol       Date:  2019-06-11       Impact factor: 2.490

3.  Assessment of Late Mortality Risk After Allogeneic Blood or Marrow Transplantation Performed in Childhood.

Authors:  Anna Sällfors Holmqvist; Yanjun Chen; Jessica Wu; Kevin Battles; Ravi Bhatia; Liton Francisco; Lindsey Hageman; Michelle Kung; Emily Ness; Mariel Parman; Donna Salzman; Aman Wadhwa; Jeanette Falck Winther; Joseph Rosenthal; Stephen J Forman; Daniel J Weisdorf; Saro H Armenian; Mukta Arora; Smita Bhatia
Journal:  JAMA Oncol       Date:  2018-12-13       Impact factor: 31.777

Review 4.  Cause-specific late mortality after allogeneic stem cell transplantation.

Authors:  Smita Bhatia
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

Review 5.  Long-term complications after hematopoietic cell transplantation.

Authors:  Navneet S Majhail
Journal:  Hematol Oncol Stem Cell Ther       Date:  2017-06-13

6.  Outcomes of patients who developed subsequent solid cancer after hematopoietic cell transplantation.

Authors:  Yoshihiro Inamoto; Tomohiro Matsuda; Ken Tabuchi; Saiko Kurosawa; Hideki Nakasone; Hisakazu Nishimori; Satoshi Yamasaki; Noriko Doki; Koji Iwato; Takehiko Mori; Satoshi Takahashi; Hiromasa Yabe; Akio Kohno; Hirohisa Nakamae; Toru Sakura; Hisako Hashimoto; Junichi Sugita; Hiroatsu Ago; Takahiro Fukuda; Tatsuo Ichinohe; Yoshiko Atsuta; Takuya Yamashita
Journal:  Blood Adv       Date:  2018-08-14

7.  Clinical trajectories, healthcare resource use, and costs of long-term hematopoietic stem cell transplantation survivors: a latent class analysis.

Authors:  Jifang Zhou; Edith A Nutescu; Jin Han; Gregory S Calip
Journal:  J Cancer Surviv       Date:  2020-01-02       Impact factor: 4.442

8.  Functional capacity, pulmonary function, and quality of life in hematopoietic stem cell transplantation survivors.

Authors:  Giana Berleze Penna; Tassiana Costa da Silva; Alessandra Aparecida Paz; Bruna Ziegler
Journal:  Support Care Cancer       Date:  2021-01-04       Impact factor: 3.359

9.  Asymmetric dimethylarginine serum levels are associated with early mortality after allogeneic stem cell transplantation.

Authors:  Aleksandar Radujkovic; Hao Dai; Lambros Kordelas; Dietrich Beelen; Sivaramakrishna P Rachakonda; Carsten Müller-Tidow; Rajiv Kumar; Peter Dreger; Thomas Luft
Journal:  Haematologica       Date:  2018-12-04       Impact factor: 9.941

10.  Donor and recipient plasma follistatin levels are associated with acute GvHD in Blood and Marrow Transplant Clinical Trials Network 0402.

Authors:  L M Turcotte; T E DeFor; L F Newell; C S Cutler; M R Verneris; J Wu; A Howard; M L MacMillan; J H Antin; G M Vercellotti; Ane Slungaard; B R Blazar; D J Weisdorf; A Panoskaltsis-Mortari; S G Holtan
Journal:  Bone Marrow Transplant       Date:  2017-10-23       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.